Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulbactam sodium is the sodium salt form of sulbactam, a beta-lactamase inhibitor and derivative of the basic penicillin nucleus. It is not typically used alone but in combination with beta-lactam antibiotics to treat bacterial infections by inhibiting beta-lactamase enzymes produced by bacteria that would otherwise degrade these antibiotics and confer resistance. Sulbactam acts as a suicide inhibitor of beta-lactamases and has weak intrinsic antibacterial activity through inhibition of penicillin-binding proteins (PBP) 1 and 3 but not PBP2[1][5][8]. Its primary clinical use is as part of injectable combinations such as ampicillin/sulbactam for treating various susceptible bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulbactam sodium.